Johnson & Johnson CIO Executes Option Exercises, Sells $15.1 Million in Stock; Company Moves Ahead on Cell Therapy Investment
Johnson & Johnson Executive Vice President and Chief Investment Officer James D. Swanson completed a series of equity transactions in mid-February 2026 that included the sale of common shares, the exercise of employee stock options and the conversion of restricted and performance share units. Those moves occurred alongside the company’s announcemen…